FR2577804A1 - Pharmaceutical compositions based on verapamil and alfuzosin - Google Patents

Pharmaceutical compositions based on verapamil and alfuzosin Download PDF

Info

Publication number
FR2577804A1
FR2577804A1 FR8502726A FR8502726A FR2577804A1 FR 2577804 A1 FR2577804 A1 FR 2577804A1 FR 8502726 A FR8502726 A FR 8502726A FR 8502726 A FR8502726 A FR 8502726A FR 2577804 A1 FR2577804 A1 FR 2577804A1
Authority
FR
France
Prior art keywords
sep
verapamil
alfuzosin
pharmaceutical compositions
compositions based
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR8502726A
Other languages
French (fr)
Other versions
FR2577804B1 (en
Inventor
Icilio Cavero
Peter Hicks
Salomon Langer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthelabo SA
Original Assignee
Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo SA filed Critical Synthelabo SA
Priority to FR8502726A priority Critical patent/FR2577804B1/en
Priority to EP86400015A priority patent/EP0189336A1/en
Priority to AU52456/86A priority patent/AU5245686A/en
Priority to DK22386A priority patent/DK22386A/en
Priority to HU24386A priority patent/HUT39604A/en
Publication of FR2577804A1 publication Critical patent/FR2577804A1/en
Application granted granted Critical
Publication of FR2577804B1 publication Critical patent/FR2577804B1/en
Priority to US07/106,968 priority patent/US4925837A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Abstract

Pharmaceutical composition containing a combination of verapamil and alfuzosin.

Description

La présente invention a pour objet des compositions pharmaceutiques a base de vérapamil et d'alfuzosire, destinées au traitement de maladies cardiovasculaires. plus particulièrement de l'hypertension quelle que soit son origine.The present invention relates to pharmaceutical compositions based on verapamil and alfuzosire for the treatment of cardiovascular diseases. especially hypertension regardless of its origin.

Le vérapamil, de formule

Figure img00010001

est connu pour ses propriétés antihypertensives, antiangineuses, antiarythmiques et antagonistes du calcum. Verapamil, of formula
Figure img00010001

is known for its antihypertensive, antianginal, antiarrhythmic and calcium antagonist properties.

L'alfuzosine, de formule

Figure img00010002

possède également des propriétés antihypertensives.Alfuzosin, of formula
Figure img00010002

also has antihypertensive properties.

La demanderesse a constaté que, de manière surprenante, il existe un effet de synergie important entre les propriétés antihypertensives des deux composés lorsqu'on les associe.The Applicant has found that, surprisingly, there is a significant synergistic effect between the antihypertensive properties of the two compounds when they are combined.

Les compositions pharmaceutiques de l'invention ont été soumises à une série d'essais pharmacologiques qui révèlent leurs intéressantes propriétés dans le domaine cardiovasculaire.The pharmaceutical compositions of the invention have been subjected to a series of pharmacological tests which reveal their interesting properties in the cardiovascular field.

Le test utilisé est le suivant : des rats spontanément hypertendus âgés de plus de 5 mois, sont placés pendant 30 mn, dans une cage à air conditionné maintenue à 280 C. La pression systolique des rats est mesurée selon la méthode décrite par Gerold et Tschirky (Arzneim. Forsch. 1968, 18, 1285).The test used is as follows: spontaneously hypertensive rats older than 5 months are placed for 30 minutes in an air conditioned cage maintained at 280 ° C. The systolic pressure of the rats is measured according to the method described by Gerold and Tschirky (Arzneim Forsch, 1968, 18, 1285).

On administre à un groupe de 6 rats spontanément hypertendus 0,3 mg/kg ou 1 mg/kg d'alfuzofine séparément ou l'association de vérapamil et d'alfuzosine.A group of 6 spontaneously hypertensive rats is given 0.3 mg / kg or 1 mg / kg of alfuzofine separately or the combination of verapamil and alfuzosin.

La pression systolique est mesurée avant l'administration des agents thérapeutiques puis 1, 2 ou 3 heures après l'administration d'un des composés ou de l'association de vérapamil et d'alfuzosine.Systolic pressure is measured prior to administration of the therapeutic agents and then 1, 2 or 3 hours after administration of one of the compounds or combination of verapamil and alfuzosin.

Les résultats sont donnés sous forme de diminutions de la pression sanguine par rapport à la pression de base.The results are given as decreases in blood pressure relative to the basal pressure.

Dans le tableau suivant sont donnés les résultats obtenus, et pour les composés administrés seuls, et pour les associations de vérapamil et d'alfuzosine. In the following table are given the results obtained, and for the compounds administered alone, and for the combinations of verapamil and alfuzosin.

Tableau

Figure img00030001
Board
Figure img00030001

<tb> <SEP> dose <SEP> pression <SEP> Diminution <SEP> de <SEP> la
<tb> Composé <SEP> mg/kg <SEP> p.o. <SEP> de <SEP> base <SEP> pression <SEP> systolique
<tb> <SEP> (mm <SEP> Hg) <SEP> (mm <SEP> Hg)
<tb> <SEP> 1h <SEP> 2h <SEP> 3h <SEP>
<tb> vérapamil <SEP> 15 <SEP> 217 <SEP> 1 <SEP> 5 <SEP> -527 <SEP> -28+9
<tb> alfuzosine <SEP> 1 <SEP> 221 <SEP> + <SEP> 2 <SEP> -154 <SEP> -23+3 <SEP> -15+5
<tb> vérapamil+ <SEP> 15+1 <SEP> 209 <SEP> 1 <SEP> 6 <SEP> -124+5 <SEP> -120+5*
<tb> alfuzosine
<tb> * Effet significativement supérieur à une simple addition des effets de chacun des composés. <tb><SEP> dose <SEP> pressure <SEP> Decrease <SEP> of <SEP> la
<tb> Compound <SEP> mg / kg <SEP> po <SEP> of <SEP> base <SEP> systolic pressure <SEP>
<tb><SEP> (mm <SEP> Hg) <SEP> (mm <SEP> Hg)
<tb><SEP> 1h <SEP> 2h <SEP> 3h <SEP>
<tb> verapamil <SEP> 15 <SEP> 217 <SEP> 1 <SEP> 5 <SEP> -527 <SEP> -28 + 9
<tb> alfuzosin <SEP> 1 <SEP> 221 <SEP> + <SEP> 2 <SEP> -154 <SEP> -23 + 3 <SEP> -15 + 5
<tb> verapamil + <SEP> 15 + 1 <SEP> 209 <SEP> 1 <SEP> 6 <SEP> -124 + 5 <SEP> -120 + 5 *
<tb> alfuzosin
<tb> * Significantly greater effect than a simple addition of the effects of each of the compounds.

Ces résultats montrent que l'association de vérapamil avec l'alfuzosine produit un effet antihypertenseur significativement plus important que la somme des effets engendrés par chacun des composés administrés isolément.These results show that the combination of verapamil with alfuzosin produces a significantly greater antihypertensive effect than the sum of the effects generated by each of the compounds administered alone.

I1 existe donc une synergie entre les effets antihypertenseurs du vérapamil et de l'alfuzosine.  There is therefore a synergy between the antihypertensive effects of verapamil and alfuzosin.

Les compositions pharmaceutiques de l'invention peuvent contenir de 30 à 120 mg de vérapamil et de 0,5 à 10 mg d'alfuzosine par unité de prise.The pharmaceutical compositions of the invention may contain from 30 to 120 mg of verapamil and from 0.5 to 10 mg of alfuzosin per unit dose.

Les compositions pharmaceutiques de l'invention peuvent être présentées sous toute forme appropriée pour l'administration par voie orale ou parentérale, en association avec tout excipient approprié.The pharmaceutical compositions of the invention may be presented in any form suitable for oral or parenteral administration, in combination with any suitable excipient.

Les compositions pharmaceutiques de l'invention peuvent être utilisées pour le traitement de l'hypertension et pour le traitement d'autres maladies telles que l'asthme, l'angine de poitrine, l'athérosclérose et les affections urologiques.The pharmaceutical compositions of the invention can be used for the treatment of hypertension and for the treatment of other diseases such as asthma, angina pectoris, atherosclerosis and urological diseases.

La posologie quotidienne est telle que l'on administre de 30 à 240 mg de vérapamil et de 0,5 à 20 mg d'alfuzosine. The daily dosage is such that 30 to 240 mg of verapamil and 0.5 to 20 mg of alfuzosin are administered.

Claims (2)

Revendicationsclaims 1. Composition pharmaceutique contenant une association de vérapamil et d'alfuzosine.1. A pharmaceutical composition containing a combination of verapamil and alfuzosin. 2. Composition selon la revendication 1 caractérisée en ce qu'elle contient de 30 à 120 mg de vérapamil et de 0,5 à 10 mg d'alfuzosine par unité de prise. 2. Composition according to claim 1 characterized in that it contains 30 to 120 mg of verapamil and 0.5 to 10 mg of alfuzosin per unit dose.
FR8502726A 1984-09-14 1985-02-26 PHARMACEUTICAL COMPOSITIONS BASED ON VERAPAMIL AND ALFUZOSINE Expired FR2577804B1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR8502726A FR2577804B1 (en) 1985-02-26 1985-02-26 PHARMACEUTICAL COMPOSITIONS BASED ON VERAPAMIL AND ALFUZOSINE
EP86400015A EP0189336A1 (en) 1985-01-18 1986-01-07 Pharmaceutical compositions containing an alpha-blocker and a calcium antagonist
AU52456/86A AU5245686A (en) 1985-01-18 1986-01-17 Compositions of alpha blocking and calcium-antagonistic compounds
DK22386A DK22386A (en) 1985-01-18 1986-01-17 MEDICINE CONTAINING A COMBINATION OF AN ALFA BLOCKER AND A CALCIUM ANTAGONIST
HU24386A HUT39604A (en) 1985-01-18 1986-01-17 Process for producing pharmaceutical compositions containing alpha-blocking agents and calcium-antagonistic agents
US07/106,968 US4925837A (en) 1984-09-14 1987-10-13 Pharmaceutical compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8502726A FR2577804B1 (en) 1985-02-26 1985-02-26 PHARMACEUTICAL COMPOSITIONS BASED ON VERAPAMIL AND ALFUZOSINE

Publications (2)

Publication Number Publication Date
FR2577804A1 true FR2577804A1 (en) 1986-08-29
FR2577804B1 FR2577804B1 (en) 1987-03-27

Family

ID=9316609

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8502726A Expired FR2577804B1 (en) 1984-09-14 1985-02-26 PHARMACEUTICAL COMPOSITIONS BASED ON VERAPAMIL AND ALFUZOSINE

Country Status (1)

Country Link
FR (1) FR2577804B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116309A (en) * 1989-01-25 1992-05-26 Coll Milton E Ureteral stent-catheter system having varying diameter stent

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2421888A1 (en) * 1978-02-06 1979-11-02 Synthelabo ALKYLENE DIAMINE AMIDES AND THEIR APPLICATION IN THERAPEUTICS
FR2466462A2 (en) * 1978-02-06 1981-04-10 Synthelabo Antihypertensive quinazoline derivs. - substd. by 2-acylamino: alkylamino group

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2421888A1 (en) * 1978-02-06 1979-11-02 Synthelabo ALKYLENE DIAMINE AMIDES AND THEIR APPLICATION IN THERAPEUTICS
FR2445323A2 (en) * 1978-02-06 1980-07-25 Synthelabo ALKYLENEDIAMINE AMIDES AND THEIR THERAPEUTIC APPLICATION
FR2466462A2 (en) * 1978-02-06 1981-04-10 Synthelabo Antihypertensive quinazoline derivs. - substd. by 2-acylamino: alkylamino group

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116309A (en) * 1989-01-25 1992-05-26 Coll Milton E Ureteral stent-catheter system having varying diameter stent

Also Published As

Publication number Publication date
FR2577804B1 (en) 1987-03-27

Similar Documents

Publication Publication Date Title
EP0462189B1 (en) Combination therapy for treatment of estrogen sensitive diseases
JP2007524627A5 (en)
CA2330500A1 (en) Pharmaceutical compositions capable of being gelled
IL149496A (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders
Iwatsuki et al. Reduction of blood pressure and vascular collagen in hypertensive rats by beta-aminopropionitrile.
FR2917975A1 (en) COMPOSITIONS AND TREATMENT OF CARDIAC INSUFFICIENCY IN NON-HUMAN MAMMAL ANIMALS
FR2639226A1 (en) USE OF TRIFLUOROMETHYLPHENYLTETRAHYDROPYRIDINES FOR THE PREPARATION OF MEDICAMENTS FOR COMBATTING ANXIO-DEPRESSIVE DISORDERS
KR20050025985A (en) Composition Containing an Androgenous 11β-Halogen Steroid and a Progestational Hormone, and Male Contraceptive Based on Said Composition
RU2017127509A (en) COMPOSITIONS AND METHODS FOR IMPROVED MUSCLE METABOLISM
JPH0725702B2 (en) Pharmaceutical composition containing diltiazem and angiotensin converting enzyme inhibitor
EP0956022A1 (en) Hormonal composition consisting of an oestrogen compound and of a progestational compound
CA2389025A1 (en) Hormonal composition based on a progesterone and an oestrogen and use thereof
FR2577804A1 (en) Pharmaceutical compositions based on verapamil and alfuzosin
EP0214881B1 (en) Pharmaceutical compositions on the basis of diltiazem and aspirin
US4925837A (en) Pharmaceutical compositions
FR2577803A1 (en) Pharmaceutical compositions based on nifedipine and alfuzosin
EP0189336A1 (en) Pharmaceutical compositions containing an alpha-blocker and a calcium antagonist
JP2008044871A (en) Cardiovascular disease-preventing and treating agent
FR2577802A1 (en) PHARMACEUTICAL COMPOSITIONS BASED ON BETAXOLOL AND NIFEDIPINE
FR2576214A1 (en) Pharmaceutical compositions based on diltiazem and an antihypertensive
FR2792199A1 (en) USE OF OSANETANT FOR THE PREPARATION OF MEDICINES USEFUL IN THE TREATMENT OF MOOD DISORDERS
JP3575033B2 (en) External preparation
FR2570275A1 (en) PHARMACEUTICAL COMPOSITIONS BASED ON DILTIAZEM AND ALFUSOZINE
EP1646373A2 (en) Orodispersible pharmaceutical composition of an antithrombotic compound
JPH05221877A (en) Combination of calcium antagonist and cholineesterase inhibitor

Legal Events

Date Code Title Description
ST Notification of lapse